At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Mohammed Jaloudi, MD, of Tawam Hospital, Al Ain, United Arab Emirates, discusses the implications of routine Oncotype DX® testing for predicting the benefit of adjuvant chemotherapy in patients with early breast cancer. Dr Jaloudi outlines some of the challenges that need to be addressed to ensure continued access to well-validated genomic tests, such as the Oncotype DX® Breast Cancer Assay, in clinical practice.
This content is supported by Genomic Health, Inc.
European Medical Journal
Advertisement
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews